Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
or

Soleno Therapeutics Inc (SLNO)

Soleno Therapeutics Inc (SLNO)
48.07 -0.71 (-1.46%) 14:16 ET [NASDAQ]
47.95 x 30 48.12 x 157
Realtime by (Cboe BZX)
47.95 x 30 48.12 x 157
Realtime - - (-) -
Quote Overview for Thu, Mar 20th, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
47.43
Day High
49.13
Open 48.26
Previous Close 48.78 48.78
Volume 173,338 173,338
Avg Vol 591,997 591,997
Stochastic %K 80.20% 80.20%
Weighted Alpha +10.80 +10.80
5-Day Change -0.90 (-1.84%) -0.90 (-1.84%)
52-Week Range 36.61 - 60.92 36.61 - 60.92
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,236,904
  • Shares Outstanding, K 45,857
  • Annual Sales, $ 0 K
  • Annual Income, $ -175,850 K
  • EBIT $ -188 M
  • EBITDA $ -186 M
  • 60-Month Beta -1.70
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 8.81

Options Overview Details

View History
  • Implied Volatility 187.56% ( -4.35%)
  • Historical Volatility 44.18%
  • IV Percentile 98%
  • IV Rank 95.82%
  • IV High 193.95% on 03/10/25
  • IV Low 41.16% on 11/26/24
  • Put/Call Vol Ratio 0.69
  • Today's Volume 383
  • Volume Avg (30-Day) 1,966
  • Put/Call OI Ratio 0.84
  • Today's Open Interest 60,847
  • Open Int (30-Day) 50,912

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate -1.08
  • Number of Estimates 5
  • High Estimate -0.78
  • Low Estimate -1.43
  • Prior Year -0.59
  • Growth Rate Est. (year over year) -83.05%

Price Performance

See More
Period Period Low Period High Performance
1-Month
43.00 +11.93%
on 03/11/25
Period Open: 47.42
50.49 -4.67%
on 03/17/25
+0.71 (+1.50%)
since 02/20/25
3-Month
41.50 +15.98%
on 01/15/25
Period Open: 45.18
52.46 -8.25%
on 02/14/25
+2.95 (+6.53%)
since 12/20/24
52-Week
36.61 +31.47%
on 04/19/24
Period Open: 44.00
60.92 -20.99%
on 11/25/24
+4.13 (+9.39%)
since 03/20/24

Most Recent Stories

More News
Soleno Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2024 Financial Results

SLNO : 48.07 (-1.46%)
Soleno Therapeutics to Participate in Upcoming February Investor Conferences

SLNO : 48.07 (-1.46%)
Soleno Therapeutics Secures Up to $200 Million in Loan Agreement with Oxford Finance

Soleno Therapeutics secures up to $200 million in financing to support its drug development and anticipated commercial activities.Quiver AI SummarySoleno Therapeutics, Inc. has secured a loan and security...

SLNO : 48.07 (-1.46%)
Soleno Therapeutics Enters Into $200 Million Debt Financing with Oxford Finance LLC

SLNO : 48.07 (-1.46%)
Soleno Therapeutics to Participate in Piper Sandler 36th Annual Healthcare Conference

SLNO : 48.07 (-1.46%)
Soleno Therapeutics Announces FDA Extension of NDA Review for DCCR Tablets in Prader-Willi Syndrome

FDA extends review of Soleno’s NDA for DCCR tablets treating Prader-Willi syndrome; new decision date is March 27, 2025.Quiver AI SummarySoleno Therapeutics, Inc. announced that the FDA has extended...

SLNO : 48.07 (-1.46%)
Soleno Therapeutics Announces FDA Extension of Review Period for DCCR (Diazoxide Choline) Extended-Release Tablets in Prader-Willi Syndrome

SLNO : 48.07 (-1.46%)
Soleno Therapeutics to Present DCCR Clinical Data for Prader-Willi Syndrome at 62nd Annual ESPE Meeting

Soleno Therapeutics will present DCCR clinical data for Prader-Willi syndrome at the upcoming ESPE Meeting in Liverpool.Quiver AI SummarySoleno Therapeutics, Inc. announced that it will present data from...

SLNO : 48.07 (-1.46%)
Soleno Therapeutics Announces Oral Presentations featuring Diazoxide Choline Extended-Release (DCCR) Tablets in Prader-Willi Syndrome at ESPE 2024

SLNO : 48.07 (-1.46%)
Soleno Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results

SLNO : 48.07 (-1.46%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 48% Sell with a Weakening short term outlook on maintaining the current direction.

See More Share

Business Summary

Soleno Therapeutics Inc. is a healthcare company. It develops and commercializes diagnostics, devices and therapeutics addressing unmet medical needs. The Company offers products consists of CoSense end-tidal carbon monoxide Monitor, NeoPIP Infant Resuscitator and Accessories and Serenz Nasal Relief....

See More

Key Turning Points

3rd Resistance Point 52.37
2nd Resistance Point 51.38
1st Resistance Point 50.08
Last Price 48.07
1st Support Level 47.78
2nd Support Level 46.79
3rd Support Level 45.49

See More

52-Week High 60.92
Fibonacci 61.8% 51.63
Fibonacci 50% 48.76
Last Price 48.07
Fibonacci 38.2% 45.90
52-Week Low 36.61

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
Precision Trading with Bollinger Bands: Identifying Breakouts & Reversals